The EU-funded PRIME Project – where EBC is a partner – kicked off in January 2020, working to explore how common molecular mechanisms may link metabolic disorders, especially type 2 diabetes and obesity, with brain disorders such as Alzheimer’s disease, obsessive-compulsive disorder, and autism spectrum disorders.

The 5-year long project (January 2020 – 31 December 2024) called ‘PRIME’ (Prevention and Remediation of Insulin Multimorbidity in Europe) aims to unravel how brain disorders throughout life can be traced to alterations in insulin signalling and how this relates to the somatic diseases type 2 diabetes and obesity. In total, 17 different university and private sector groups from 9 different European countries will participate in PRIME, which will receive €6 million funding from the EU’s Horizon 2020 programme.